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Abstract
Liver transplantation has been reported to initiate increases in
procalcitonin levels, in the absence of bacterial infection. The
results of a study investigating the course of procalcitonin levels
over several days after liver transplantation in noninfected patients
were recently reported in Critical Care. This study shows that
procalcitonin levels increase only transiently, immediately after
surgery, and thereafter they rapidly decrease. This new information
gives us hope that procalcitonin can be used as a marker of
bacterial infection in these patients. Further studies of patients
undergoing liver transplantation with and without bacterial infection
are needed.
Recently in Critical Care, Zazula and colleagues [1] reported
a study in which they conducted daily measurement of the
biomarker procalcitonin in patients undergoing liver trans-
plantation and resection. The findings provide novel clinical
and molecular information on this biomarker.
In patients with severe organ impairment and in critically ill
patients, bacterial infection is both common and among the
most feared complications, because these infections are
associated with a high rate of mortality that increases if they
are left untreated [2,3]. Among the various outcome para-
meters identified to date in patients with septic shock, time to
administration of appropriate antimicrobial treatment has
been documented to be the factor most predictive of
outcome, with survival probability dropping from 83% to 8%
with an antibiotic delay of 24 hours. It is a tragic reality that
timely diagnosis, monitoring and hence treatment of bacterial
infection is frequently not possible in these unconscious,
heavily medicated, immunocompromised patients, in whom
there is an ongoing inflammatory response caused by
multiple factors other than bacterial infection [4].
For these reasons, transplant specialists have long sought a
reliable biomarker to assist them in identifying the right
treatment at the right time. Procalcitonin has been suggested
to be a useful biomarker for this purpose, because it exhibits
a favourable kinetic profile as compared with, for instance, C-
reactive protein and leucocyte count. It has been also
proposed to be more specific for bacterial infection than
established markers [5,6]. However, the findings of many
studies call into question these proposed advantages of
procalcitonin as compared with conventional markers; these
were summarized by Tang and coworkers [7]. Some
investigators have found that procalcitonin exhibits high
sensitivity and specificity in identifying patients with sepsis,
especially in populations in which the sepsis syndrome is
most often caused by bacterial infection (for example,
intensive care unit patients) [6]. Other investigators were
unable to reproduce these findings, especially in populations
in which the sepsis syndrome is frequently not caused by
bacterial infection (for instance, patients presenting at
emergency departments) [8].
The difference in performance of procalcitonin reported in
these clinical investigations may be accounted for by the
‘gold standard’ problem and by differences between dynamic
and static measurements. Assessment of the clinical value of
a biomarker requires that the gold standard be accurate.
Sepsis does not necessarily reflect ongoing bacterial
infection; many patients with sepsis satisfy two criteria for
systemic inflammatory response syndrome, together with ‘a
suspicion of infection’, without actually being infected with
bacteria. This mainly affects the sensitivity of the marker.
Regarding the second cause of discrepant findings in studies
of procalcitonin, namely the difference between dynamic and
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static approaches to measurement, many clinical conditions
(mainly those that influence function of the gut) result in
transient increases in plasma procalcitonin level, possibly
resulting from translocation of bacterial products from the gut
lumen to the blood. An initial measurement of procalcitonin
immediately after surgery and during a hypotensive period
(and other circumstances) uniformly shows elevation, even if
a bacterial infection is not established [9]. The logical
consequence of this is that if a strategy involving a solitary
initial measurement is selected, then this will often result in
‘false positive’ procalcitonin results. This factor mainly affects
the specificity of the marker.
Casuistic reports have indicated that procalcitonin is high
after liver transplantation in patients without evidence of
ongoing invasive bacterial infection, and that this may lead to
diagnostic misinterpretation [10].
Zazula and colleagues [1] reported an alternative and
interesting approach, based on current knowledge on
transient procalcitonin increases after surgery. Specifically,
they measured this biomarker for several consecutive days
after liver transplantation and resection. The findings of the
study are interesting for two reasons. First, as in major
abdominal surgery, procalcitonin levels increase transiently
for about 24 hours after liver transplant and thereafter they
decrease rapidly if no bacterial infection is present. This adds
some useful clinical information regarding the time interval
over which procalcitonin measurements should be taken in
this patient population to distinguish between nonspecific
elevations and elevations caused by ongoing bacterial
infection (specifically, several consecutive measurements are
needed). Second, the level of this transient increase is highly
dependent on the type of immunomodulatory therapy the
patient is receiving, which gives insight into the physiology
and pathophysiology of the procalcitonin polypeptide. Zazula
and colleagues provide some relevant interpretation of the
findings, extrapolating from the fact that the polyclonal
antithymocyte globulin is produced by immunizing rabbits
with the human Jurkat T-cell line. As explained in the report,
one of the molecules expressed by this cell line is intercellular
adhesion molecule-1 (CD54), which is involved in ischaemia-
related inflammation, and treatment with polyclonal anti-
thymocyte globulin can thereby potentially mimic ischaemia-
related inflammation. This is especially interesting because
severe human organ ischaemia causes procalcitonin level to
increase, sometimes to high levels, and this could represent
an alternative explanation for the procalcitonin increases
observed after prolonged hypotension.
Where do these observations lead us? An important follow-
up study would be to quantify the extent to which consecutive
determinations of procalcitonin plasma levels actually alert
the physician to the presence of ongoing invasive bacterial
infections soon after this infection is established. Even more
importantly, does access to procalcitonin levels provide an
opportunity to intervene with antibacterial therapy at an earlier
time point in the course of the bacterial infection and to
employ other routinely available clinical and laboratory-based
assessments, thereby improving prognosis? Introduction of
routine use of novel biomarkers should be based on
demonstration of a benefit when they are applied to a target
patient population; hence, it is critical that these questions be
addressed before procalcitonin is introduced as a screening
tool in patients undergoing liver transplantation. It is hoped
that the results of ongoing randomized trials of procalcitonin-
guided antibacterial treatment of critically ill patients,
powered to assess whether daily procalcitonin measure-
ments can improve survival rates, will inform this discussion.
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